🇺🇸 FDA
Pipeline program

UBT251

TUL-UBT251(Ⅱ-3)202501

Phase 2 small_molecule active

Quick answer

UBT251 for Metabolic Dysfunction-associated Steatohepatitis (MASH) is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials